AbbVie Inc
NYSE:ABBV

  • LAST PRICE
    164.9900
  • TODAY'S CHANGE (%)
    -4.6400 (-2.7354%)
  • Bid / Lots
    165.0000/ 2
  • Ask / Lots
    165.3000/ 1
  • Open / Previous Close
    169.6300 / 169.6300
  • Day Range
    164.7200
    169.6300
  • 52 Week Range
    136.2966
    207.3200
  • Volume
    11,265,398

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Nov 14, 2024

      Show headlines and story abstract

    • 8:15AM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: ABBV

      -- AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine

      -- AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace

    • 8:15AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: ABBV

      US-NEUM-240098

      References:
      1. Adams AM, Serrano D, et al. Perceived effect of migraine on career and finances: results of the chronic migraine epidemiology and outcomes (CaMEO). ClinicalTrials.gov identifier: NCT01648530. Updated January 29, 2015. Accessed January 19, 2024. clinicaltrials.gov/ct2/show/NCT01648530. 2. American Migraine Foundation. What is migraine? January 21, 2021. Accessed January 31, 2024. https://americanmigrainefoundation.org/resource-library/what-is-migraine/ 3. World Health Organization. Migraine and other headache disorders. March 6, 2024. Accessed October 1, 2024. https://www.who.int/news-room/fact-sheets/detail/headache-disorders 4. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1-211. 5. Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, Sullman MJM, Kolahi AA, Safiri S. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605. PMID: 35281991; PMCID: PMC8904749. 6. Steiner, T. J., Stovner, L. J., Vos, T., Jensen, R., & Katsarava, Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17. 7. AbbVie. Data on File: ABVRRTI73750. 8. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86-92.

Peers Headlines